Compare GKOS & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | CPB |
|---|---|---|
| Founded | 1998 | 1869 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.2B |
| IPO Year | 2015 | 1994 |
| Metric | GKOS | CPB |
|---|---|---|
| Price | $102.43 | $21.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 18 |
| Target Price | ★ $126.92 | $26.06 |
| AVG Volume (30 Days) | 1.0M | ★ 6.5M |
| Earning Date | 04-29-2026 | 06-01-2026 |
| Dividend Yield | N/A | ★ 7.63% |
| EPS Growth | N/A | ★ 6.35 |
| EPS | N/A | ★ 1.13 |
| Revenue | $507,442,000.00 | ★ $10,253,000,000.00 |
| Revenue This Year | $23.32 | N/A |
| Revenue Next Year | $27.43 | $0.11 |
| P/E Ratio | ★ N/A | $18.43 |
| Revenue Growth | ★ 32.33 | 6.40 |
| 52 Week Low | $73.16 | $19.56 |
| 52 Week High | $148.11 | $35.00 |
| Indicator | GKOS | CPB |
|---|---|---|
| Relative Strength Index (RSI) | 28.38 | 55.48 |
| Support Level | $92.38 | $19.78 |
| Resistance Level | $102.80 | $21.31 |
| Average True Range (ATR) | 7.36 | 0.63 |
| MACD | -4.94 | 0.12 |
| Stochastic Oscillator | 1.08 | 82.09 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.